Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Immix Biopharma, Inc. (IMMX) had Return on Tangible Equity of -31.39% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-29.44M |
|
-- |
|
-- |
|
$29.96M |
|
$-29.96M |
|
$0.56M |
|
$-29.40M |
|
$-29.40M |
|
$-29.44M |
|
$-29.44M |
|
$-29.44M |
|
$-29.44M |
|
$-29.96M |
|
$-29.59M |
|
32.97M |
|
32.97M |
|
$-0.89 |
|
$-0.89 |
|
| Balance Sheet Financials | |
$101.24M |
|
$2.52M |
|
$3.60M |
|
$104.84M |
|
$10.11M |
|
-- |
|
$0.93M |
|
$11.04M |
|
$93.80M |
|
$93.80M |
|
$93.80M |
|
52.95M |
|
| Cash Flow Statement Financials | |
$-23.93M |
|
$-7.21M |
|
$107.39M |
|
$17.68M |
|
$93.93M |
|
$76.25M |
|
$2.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.39% |
|
|
Return on Tangible Equity |
-31.39% |
-28.08% |
|
-31.39% |
|
$1.77 |
|
$-0.75 |
|
$-0.73 |
|